BMO Capital Maintains Outperform on National Health Investors, Lowers Price Target to $80

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

BMO Capital analyst Juan Sanabria maintains National Health Investors (NYSE:NHI) with a Outperform and lowers the price target from $90 to $80.